Cerebras (CBRS) Stock Dips Despite Finland AI Data Center Expansion and Ark Invest Buying Spree

Key Takeaways

Table of Contents

CBRS shares declined 3.6% to $177.50 on Tuesday following announcement of a new Finland AI data center partnership
The Mikkeli facility will achieve 165 MW of IT capacity, with initial 50 MW phase already in development
Cathie Wood’s Ark Invest purchased approximately $17 million worth of CBRS shares on Aug. 25, signaling confidence in AI inference
Second quarter revenue reached $180.1 million, representing 74% year-over-year growth, while cloud revenue soared 287% YOY
Analysts maintain consensus “Strong Buy” rating with average price target of $283.91, suggesting approximately 59% upside potential

Shares of Cerebras Systems (CBRS) retreated 3.6% to $177.50 during Tuesday’s trading session, despite the artificial intelligence chip maker unveiling a significant data center partnership in Finland. The stock has tumbled more than 42% over the trailing twelve months and currently trades over 15% beneath its 20-day moving average.

Cerebras Systems Inc., CBRS

The Finnish collaboration involves Compute Nordic Finland and encompasses a new artificial intelligence data center located in Mikkeli. Planned for phased development, the installation will ultimately deliver 165 MW of contracted IT capacity. Development of the initial 50 MW phase is currently in progress.

Under the agreement’s structure, each service order includes a seven-year commitment, providing Cerebras with stable, long-term infrastructure to power its AI computing platform. The initiative is anticipated to generate employment opportunities throughout the Mikkeli area.

The share price decline accompanying favorable news isn’t particularly unusual. Market conditions were challenging overall, with the Nasdaq (QQQ) sliding 1.5% and the S&P 500 retreating 0.76%. AI infrastructure stocks typically track broader growth sentiment.

From a technical perspective, CBRS is positioned below both its 20-day SMA of $212.57 and its 50-day SMA of $203.90. The MACD indicator sits beneath its signal line accompanied by a negative histogram, suggesting weakening momentum. Critical support exists at $173.50, just above the 52-week low of $160.81.

Ark Invest Increases Position

Despite the stock’s decline, Ark Invest was actively accumulating shares. On Aug. 25, Ark acquired 93,290 CBRS shares distributed across several ETFs, totaling approximately $17.2 million. This follows previous purchases completed earlier in August.

Cathie Wood’s investment rationale focuses on Cerebras’ competitive advantage in AI inference. The company’s CS-4 system reportedly delivers up to 30 times faster inference performance compared to GPU-based solutions. Cerebras is also collaborating with AMD on a disaggregated inference architecture that provides up to five times greater throughput per watt in specific configurations.

The firm maintains strategic partnerships with OpenAI, AWS, and AMD, while simultaneously developing an inference cloud business to complement its hardware revenue streams.

Impressive Growth, Premium Pricing

Cerebras disclosed Q2 revenue of $180.1 million, reflecting 74% year-over-year expansion. Core revenue climbed to $209.9 million, up 103% YOY. Cloud and services revenue exploded 287% YOY to $127.7 million, while core gross margin advanced to 41%.

Leadership increased full-year fiscal 2026 core revenue projections to a range of $880 million to $890 million. Third quarter core revenue guidance was established at $214 million to $216 million.

The company concluded Q2 holding $8.6 billion in cash, restricted cash, and short-term investments, alongside $25.4 billion in remaining performance obligations. Additionally, it has secured more than 600 MW of data center capacity either operational or contractually committed.

The valuation commands a significant premium. With a market capitalization around $42.5 billion against annual sales of approximately $510 million, the price-to-sales multiple stands at 60 times. The company continues reporting GAAP losses.

Wall Street maintains an optimistic stance despite the elevated valuation. Among 11 analysts covering the stock, eight assign “Strong Buy” ratings, one “Moderate Buy,” and two “Hold.”

The consensus price target stands at $283.91. UBS maintains a $330 objective, Morgan Stanley elevated its target to $279, and Wedbush increased its forecast to $290.

The upcoming earnings announcement is projected for November 19, 2026, with analyst consensus anticipating revenue of $214.90 million and an EPS loss of 14 cents.

✨ Limited Time Offer